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Kinase in Brain Endothelial Cells
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for Neurovirology and Neurodegenerative Disorders,† University
of Nebraska Medical Center, Omaha, Nebraska; the Department
of Chemistry,§ University of Nebraska, Lincoln, Nebraska; and the
Department of Cell Pharmacology,¶ Nagoya University Graduate
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Critical to the proper maintenance of blood-brain-
barrier (BBB) integrity are the endothelial tight junc-
tions (TJs). Posttranslational modifications of essen-
tial endothelial TJ proteins, occludin and claudin-5,
contribute and possibly disrupt BBB integrity. Our
previous work has shown that Rho kinase (RhoK)
activation mediates occludin and claudin-5 phosphor-
ylation resulting in diminished barrier tightness and
enhanced monocyte migration across BBB in the set-
ting of human immunodeficiency virus-1 encephalitis
(HIVE). To determine whether RhoK can directly
phosphorylate TJ proteins, we examined phosphor-
ylation of cytoplasmic domains of recombinant clau-
din-5 and occludin by RhoK. We found that RhoK
predominately phosphorylated two sites on occludin
(T382 and S507) and one site on claudin-5 (T207).
Specific anti-phosphopeptide antibodies were devel-
oped for these sites, allowing the detection of phos-
phorylated occludin at T382 and S507, and claudin-5
at T207 from full-length recombinant occludin and
claudin-5 transiently expressed in COS-7 cells and
mouse brain microvascular endothelial cells. Finally,
these phosphospecific antibodies demonstrated en-
hanced staining of brain endothelial cells in the
mouse model for HIVE and human HIVE brains fea-
turing mononuclear cell infiltration across disrupted
BBB. Our results demonstrated the direct phosphory-
lation of occludin and claudin-5 by RhoK at specific
sites, which was increased in encephalitic brain tis-
sue. These antibodies could be useful reagents for
monitoring BBB dysfunction in vivo. (Am J Pathol
2008, 172:521–533; DOI: 10.2353/ajpath.2008.070076)
The blood-brain-barrier (BBB) is composed of special-
ized nonfenestrated brain microvascular endothelial cells
(BMVECs) connected by tight junctions (TJs) in an im-
permeable monolayer devoid of transcellular pores.1 TJs
are composed of claudins and occludin (OCC, integral
membrane proteins) and intracellular proteins, zonula oc-
cludens (ZO-1 to ZO-3).2 OCC (65-kDa protein) is highly
expressed in BMVECs, and it is consistently found along
the cell borders of brain endothelium.3,4 OCC is com-
posed of four transmembranous domains with the car-
boxyl and amino terminals oriented to the cytoplasm and
two extracellular loops (44 amino acids and 45 amino
acids) spanning the intercellular cleft.5 OCC content is
much lower in endothelial cells outside of the central
nervous system6,7 suggesting its active role in BBB func-
tion. The phosphorylation state of OCC regulates its as-
sociation with the cell membrane and barrier permeabil-
ity, and multiple phosphorylation sites have been
identified on OCC serine and threonine residues.8–10 The
cytoplasmic C-terminal domain provides the connection
of OCC with the cytoskeleton via accessory proteins,
ZO-1 and ZO-2.11
Up to 24 claudins (20- to 24-kDa proteins) sharing the
high sequence homology in the first and fourth trans-
membranous domains and extracellular loops have been
identified in mammals.12 Contiguous staining for claudins
is found along endothelial cell borders in and outside the
central nervous system. BMVECs express predominantly
claudin-3 and -5 (CLD5).3,13 The homophilic and hetero-
philic interactions between the extracellular loops of clau-
Supported in part by the National Institutes of Health (research grants P01
NS043985, R01 AA015913, and R01 MH65151 to Y.P.; R01 MH072539 to
T.I.; and National Center for Research Resources P20RR15635 to T.I. and
R.L.C.).
M.Y. and S.H.R. contributed equally in this study.
Accepted for publication October 16, 2007.
Address reprint requests to Tsuneya Ikezu, M.D., Ph.D., 985880 Nebraska
Medical Center, Omaha, NE 68198-5880. E-mail: tikezu@unmc.edu, Yuri
Persidsky, M.D., Ph.D., 985215 Nebraska Medical Center, Omaha, NE
68198-5215. E-mail: ypersids@unmc.edu.
The American Journal of Pathology, Vol. 172, No. 2, February 2008
Copyright © American Society for Investigative Pathology
DOI: 10.2353/ajpath.2008.070076
521
dins ensure tight contacts of the cell monolayers.14 Al-
though overexpression of claudins can induce cell
aggregation and formation of TJ-like structures, OCC
expression does not result in TJ formation.15 Nitta and
colleagues13 demonstrated that CLD5 is a critical deter-
minant of BBB permeability in mice. Thus, it appears that
claudins form the primary makeup of the TJs, and OCC
further enhances TJ tightness.
The Rho family of small dimeric G proteins (GTPases,
RhoA, Rac, Cdc42) are regulatory molecules that provide
a link between membrane receptors and actin cytoskel-
eton and contribute to the regulation of endothelial barrier
function, transendothelial leukocyte migration, and in-
flammation.16 Stimulation with proinflammatory cytokines
or leukocyte binding to adhesion molecules on endothe-
lial cells results in RhoA and Rac1 activation leading to
increased leukocyte adhesion and opening of intercellu-
lar gaps that allow leukocyte extravasation.17–19
Previously, we demonstrated that interactions between
human immunodeficiency virus (HIV)-1-infected mono-
cytes and BMVECs leads to RhoA activation, phosphor-
ylation of TJ proteins, and decreased tightness of the
BBB.20 Furthermore, significant BBB injury (documented
by disruption of CLD5/OCC staining) was detected in
human brain tissues affected by HIV-1 encephalitis
(HIVE), and monocytes co-cultured with BMVECs led to
OCC and CLD5 phosphorylation via activation of RhoA
and its downstream effector RhoK.20 Consequently, inhi-
bition of RhoA and RhoK blocked monocyte migration,
prevented TJ phosphorylation and BBB leakiness. How-
ever, it was not clear whether RhoK could phosphorylate
TJ proteins directly, and if so, which phosphorylation
sites are targeted. In this study using recombinant RhoK
and the C-terminal domains of CLD5 and OCC, we dem-
onstrate the direct phosphorylation of OCC and CLD5 by
RhoK. Also, using phosphopeptide mapping, phosphor-
ylated sites on these two TJ protein domains were char-
acterized and phosphospecific antibodies generated.
Lastly, application of these antibodies proved useful in
detecting alterations to the brain endothelium of HIV-1
encephalitic mice.
Materials and Methods
Preparation of Recombinant Glutathione
S-Transferase-RhoK Fusion Protein
(GST-RhoK), Histidine-Tagged Cytoplasmic
Domain of Occludin (OCC-CT), and
Cytoplasmic Domain of Claudin-5 (CLD5-CT)
A baculovirus expression vector of GST-RhoK, containing
the catalytic domain (6 to 553 amino acids) of RhoK, was
cloned and kindly provided by Dr. Kozo Kaibuchi at
Nagoya University, Nagoya, Japan. Fusion proteins from
the construct were produced in SF9 insect cells, using
the baculovirus expression system, and purified by glu-
tathione-Sepharose 4B (Pharmacia/GE Health Care,
Pittsburgh, PA) column as described earlier.21 6xHisti-
dine-tagged OCC-CT encoding the cytoplasmic region
(378 to 521 amino acids) of mouse OCC was generated
by subcloning the corresponding cDNA fragment (kindly
provided by Dr. Shoichiro Tsukita, Kyoto University,
Kyoto, Japan) into the BamHI-EcoRI sites of pET28a
Escherichia coli expression vector (Novagen/EMD Bio-
science, San Diego, CA), induced by 0.1 mmol/L isopro-
pyl--D-thiogalactopyranoside (Sigma-Aldrich, St. Louis,
MO) in BL21DE3 E. coli (Novagen), and purified on a
Ni-NTA column (Novagen). The His-tag sequence of pu-
rified OCC-CT was cleaved by thrombin (Sigma), which
was removed by dialysis of the sample using Slide-A-
Lyzer (molecular weight cutoff of 3.5 kDa; Pierce Biotech-
nology, Inc., Rockford, IL). The purity of the OCC-CT and
GST-RhoK was determined as 90% by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
and R-250 Coomassie brilliant blue staining. The cyto-
plasmic C terminus domain of mouse claudin-5 (CLD5-
CT, amino acids 199 to 218: KYSAPRRPTANGDYD-
KKNYV) was prepared as purified synthetic peptide with
100% purity (Alpha Diagnostic International, San Antonio,
TX).
Phosphorylation Assay
The kinase reaction of substrate with purified GST-RhoK
was performed in 50 l of reaction buffer (50 mmol/L
Tris/HCl at pH 7.5, 2 mmol/L EGTA, 1 mmol/L EDTA, 5
mmol/L MgCl2) containing 200 mol/L [-
32P] ATP (5 Ci;
Perkin Elmer, Wellesley, MA), 0.5 g purified RhoK, and
the indicated amount of bovine myosin light chain (MLC,
Sigma), purified OCC-CT recombinant protein, or
CLD5-CT peptide. After incubation at 30°C, the reaction
mixtures for MLC and OCC-CT were boiled in Laemmli
sampling buffer22 and subjected to SDS-PAGE. The ra-
diolabeled bands were visualized and quantified by a
phosphoimager (Typhoon System; Amersham Pharmacia
Biotech, Arlington Heights, IL). For CLD5 peptides, the
reaction mixtures were boiled and spotted onto phospho-
cellulose membrane (P81; Whitman, Maidstone, UK). The
spots were excised and radioactivity levels were mea-
sured by liquid scintillation counter (Beckman Coulter,
Inc., Fullerton, CA).
Liquid Chromatography/Tandem Mass
Spectrometry (LC/MS/MS)
OCC-CT and CLD5-CT were phosphorylated by incuba-
tion with GST-RhoK in reaction buffer (50 mmol/L Tris/HCl
at pH 7.5, 2 mmol/L EGTA, 1 mmol/L EDTA, 5 mmol/L
MgCl2, 200 mol/L ATP) at 30°C for 20 hours. The sam-
ples were separated by SDS-PAGE and the stained
bands were excised and subjected to LC/MS/MS analy-
sis as described.23 Briefly, in-gel trypsin digestion was
performed (Promega, Madison, WI), and the digested
peptides were extracted in 5% formic acid/50% acetoni-
trile and separated using a C18 reversed phase LC col-
umn (Dionex, Sunnyvale, CA).
A quadrupole-time of flight (Q-TOF) Ultima tandem
mass spectrometer (Waters, Milford, MA) with electros-
pray ionization was used to analyze the eluting peptides.
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The system was user-controlled using the MassLynx soft-
ware v3.5 (Waters) in data-dependent acquisition mode
with a 1-second survey scan (380 to 1900 Da) followed
by up to three 2.4-second MS/MS acquisitions (60 to
1900 Da). The instrument was operated at a mass reso-
lution of 8000 and was calibrated using the fragment ion
masses of doubly protonated Glu-fibrinopeptides.
Database searches of the acquired MS/MS spectra
were performed using Mascot (v1.9.0; Matrix Science,
Boston, MA). The database was restricted to mouse pro-
teins. The search parameters were as follows: no restric-
tions on protein molecular weight or pI, enzymatic spec-
ificity was set to trypsin, and phosphorylation was
allowed as a variable peptide modification. Only peptides
that gave a Mascot score greater than 13 (P  0.05) for
phosphorylated forms were considered as positive
identifications.
Determination of Phosphorylation Sites of
OCC-CT and CLD5-CT by RhoK by
Synthetic Peptides
Because LC/MS/MS was unable to sequence lysine- or
arginine-rich sequence after tryptic digestion of proteins,
the following peptides were synthesized to examine their
phosphorylation by GST-RhoK: KRAPTKGKAG (peptide
1, OCC 378-387), KQLKSKLAHIK (peptide 2, OCC 500-
510 with S507A mutation), KQLKAKLSHIK (peptide 3,
OCC 500-510 with S504A mutation), KYSAPRRPAA
(peptide 4, CLD5 199-208 with T207A mutation), and
KYSAPRRPTANGDYDKKNYV (peptide 5, CLD5 199-
208). The phosphorylation assay for these peptides
was performed as described.
Production of Phosphopeptide Antibodies for
OCC and CLD5
Rabbits were immunized with phosphopeptides correspond-
ing to OCC phospho-T382 [CKRAPT(PO4)KGKAGKG], OCC
phospho-S507 [CKQLKSKLS(PO4)HIKRMV], or CLD5
phospho-T207 [CAPRRPT(PO4)ANGDYDK] conjugated
with keyhole limpet hemocyanin at their NH2-terminal
cysteine residue, followed by injection of complete
Freund’s adjuvant (Biosynthesis Inc., Lewisville, TX). Af-
ter three boosts of antibody titer by peptide injection,
antisera were preadsorbed three times with affinity col-
umn immobilized with corresponding nonphosphorylated
synthetic peptide to remove nonspecific anti-peptide an-
tibodies in the sera, followed by affinity purification us-
ing phosphopeptide column. The working dilutions of
affinity-purified phosphopeptide antibodies were opti-
mized using immuno-dot-blotting of synthetic phos-
pho- and nonphosphopeptides.
Transfection, Immunoprecipitation, and Western
Blotting
COS-7 cells were plated at 3  106 cells in 10-cm culture
dishes and maintained in Dulbecco’s modified Eagle’s
medium containing 10% fetal bovine serum. Constructs
expressing either mouse OCC or CLD5 cDNA (cloned in
pCDNA3.1; Invitrogen, Carlsbad, CA) were then trans-
fected into COS-7 using LipofectAmine 2000 (Invitrogen).
After 24 hours after transfection, cells were rinsed and
treated (as indicated) for 24 hours with media containing
the RhoK inhibitor, Y27632 (Calbiochem, La Jolla, CA).
After incubation cells were rinsed twice with phosphate-
buffered saline (PBS) and scraped in radioimmunopre-
cipitation assay (RIPA) buffer containing a broad speci-
ficity protease inhibitor cocktail (1:500 dilution, Sigma).
Lysates were then triturated using a 21-gauge needle
and centrifuged at 10,000  g for 5 minutes at 4°C.
Protein concentration was then determined by bicincho-
ninic acid protein assay (Pierce), and 400 g of total
protein from each condition was used for immunoprecipi-
tation. Immunoprecipitation was performed using protein
A/G Plus-agarose beads (Santa Cruz Biotechnology,
Santa Cruz, CA) following the manufacturer’s recommen-
dations. Briefly, the lysates were immunoprecipitated with
commercial antibodies to OCC-1 (20 g, Invitrogen) and
CLD5 (20 g; US Biologicals, Swampscott, MA) and
subsequently precipitated with protein A/G agarose
beads at 4°C overnight. Samples were rinsed several
times with RIPA buffer and then boiled in 40 l of SDS
sample buffer for 5 minutes. Samples were loaded and
resolved on SDS-PAGE (4 to 20% gradient gels, Pierce)
and blotted to 0.2 m nitrocellulose membranes (Amer-
sham). Membranes were then probed with the commer-
cial antibodies (described above) or the following gener-
ated phosphospecific antibodies: OCC (pT382, 1:500)
and CLD5 (pT207, 1:500). Bound primary antibodies
were detected with horseradish peroxidase-linked sheep
anti-mouse or rabbit secondary antibodies (Abs)
(1:15,000, Pierce), followed by addition of Supersignal
West Pico chemiluminescent substrate (Pierce). Subse-
quent signal visualization was performed using the gel
documentation system, G:Box Chemi HR16 (Syngene,
Frederick, MD).
Transendothelial Electrical Resistance (TEER)
TEER was measured in real-time using the ECIS system
(model 1600R; Applied Biophysics, Inc., Troy, NY), which
was specifically designed to measure true barrier func-
tion, including resistance and capacitance. We used
bEnd3 endothelial cell line (obtained from the American
Type Tissue Collection, Manassas, VA) possessing func-
tional characteristics of BMVECs (TJs, transporters, for-
mation of tight monolayers, and response to astrocytic
factors).24,25 bEnd3 cells were grown to confluence on
collagen type I-coated ECIS cultureware arrays (model
8W10E; Applied Biophysics, Inc.). Then, measure-
ments were recorded with the following settings: cur-
rent (1-volt), frequency (400 Hz), at 3-minute intervals.
Both data acquisition and processing were performed
using the ECIS data analysis software supplied by
Applied Biophysics. The tightness of the endothelial
barrier was indicated by TEER readings (typically
2600 /cm2). Treatments were performed as indi-
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cated in the figure legends, and the data were repre-
sented as normalized resistance, which is the resis-
tance measured after treatment over the resistance
acquired before treatment introduction.
Human Peripheral Blood Lymphocytes in
Nonobese Diabetic Severe Combined
Immune-Deficient (Hu-PBL NOD/SCID) Mouse
Model of HIVE
Monocytes and peripheral blood lymphocytes (PBLs)
were obtained by countercurrent centrifugal elutriation of
leukopheresis packs from HIV-1-, HIV-2-, and hepatitis
B-seronegative donors.26 Monocytes were cultured in
suspension using Teflon flasks in Dulbecco’s modified
Eagle’s medium (Sigma) supplemented with 10% heat-
inactivated pooled human serum, 1% glutamine, 50
g/ml gentamicin, 10 g/ml ciprofloxacin (Sigma). If nec-
essary, 1000 U/ml highly purified recombinant human
macrophage colony-stimulating factor was added to the
cultures for differentiation into monocyte-derived macro-
phages (MDMs). MDMs (after 7 days in culture) were
infected for 18 hours with macrophage-tropic strain HIV-
1ADA at multiplicity of infection of 0.1.
26 The SCID mice
(male NOD/C.B-17scid, 4 weeks old) were purchased
from the Jackson Laboratory (Bar Harbor, ME). Animals
were maintained in sterile microisolator cages under
pathogen-free conditions in the Laboratory of Animal
Medicine at the University of Nebraska Medical Center in
accordance with ethical guidelines for care of laboratory
animals set forth by the National Institutes of Health.
Animals were injected intraperitoneally with rat anti-
CD122 (0.25 mg/mouse) 3 days before PBL transplanta-
tion and twice with rabbit asialo-GM1 antibodies (0.2
mg/mouse) (Wako, Richmond, VA) 1 day before and 3
days after PBL injection (2 107 cells/mouse). HIV-1ADA-
infected MDMs (5 l of suspension containing 3  105
HIV-infected cells) were injected intracerebrally27 8 days
after PBL reconstitution generating hu-PBL-NOD/SCID
HIVE mice.28 Animals were sacrificed at 7, 14, and 21
days after inoculation.
Histopathology
Brain tissues collected at necropsy were snap-frozen in
precooled isopentane or fixed in 4% phosphate-buffered
paraformaldehyde and paraffin-embedded. Immunohis-
tochemistry was performed on 10-m frozen or 5-m
paraffin sections. The following Abs were used to detect
total OCC and CLD5 (TJs, 1:50; Zymed, South San Fran-
cisco, CA), phosphorylated forms of OCC/CLD5 (using
novel antibodies described in this report), vimentin (all
human leukocytes, 1:50; DAKO, Carpinteria, CA), CD4/
CD8 (human lymphocytes, 1:25; DAKO), CD68 (human
MDM, 1:100; DAKO), vWF (BMVECs, 1:100; DAKO) (data
not shown), glial fibrillary acid protein (astrocytes, 1:100;
DAKO), Iba1 (microglia, 1:500; Wako Corp., Osaka, Ja-
pan), HIV-1 p24 antigen (1:10, DAKO).28,29 Mouse neu-
rons were labeled with mAbs for the neurofilament (NF,
1:100; DAKO).30 For immunofluorescence, Alexa fluor-
594-conjugated secondary Abs (at 1:400 dilution, Invitro-
gen) were introduced to the tissue sections at room tem-
perature for 1 hour. After four rinses with PBS, the cells
were analyzed under fluorescence microscopy using an
epifluorescence Eclipse 80i microscope (Nikon, Tokyo,
Japan), fitted with a CoolSnap-EZ digital camera (Photo-
metrics, Tucson, AZ). Image acquisition/analysis was
performed with Image-Pro (Media Cybernetics, Silver
Spring, MD).
Figure 1. Dose-dependent analysis of phosphorylation of CLD5-CT peptide,
MLC, and OCC-CT by GST-RhoK. A and C: Increasing doses of OCC-CT (0 to
5 mol/L, A) or MLC (0 to 12 mol/L, C) were incubated with [-32P] ATP and
purified GST-RhoK and separated on SDS-PAGE, followed by R-250 Coo-
massie brilliant blue staining (CBB, top) and autoradiogram (middle) of
OCC-CT (A) or MLC (C). B: Increasing doses of CLD5-CT (0 to 1200 mol/L,
B) or were phosphorylated by GST-RhoK, and spotted onto phosphocellu-
lose membrane. After extensive washing, the 32PO4 incorporation was visu-
alized by Typhoon Phosphoimager. C: Bottom shows the CBB-stained
GST-RhoK on the same gel.
Table 1. Semiquantitative Assessment of Levels of TJ
Protein Immunoreactivity Performed (n  5 Serial
Sections) Utilizing a Scale System Ranging from 0
to 3
Control
SCID
(n  3)
HIVE
SCID
(n  7)
Control
human
cases
(n  2)
HIVE
human
cases
(n  4)
CLD5-pT207 0 3 0.5 3
OCC-pT382 0 1 N/A N/A
OCC-pS507 0 2 1 3
Total CLD5 3 1.5* 3 1*
Total OCC 3 1* 3 1*
Scores of 0  no positive staining in five 20 fields (1.0 mm2 each);
1  weak staining in less than 25% of microvessels; 2  strong
staining in 30 to 60% of microvessels; 3  strong staining in more than
70% of microvessels.
*Fragmented staining for TJ proteins was seen in HIVE human
cases and HIVE mice.
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Human Brain Tissue
Frontal cortex specimens derived from four HIVE cases of
different severity (two severe and two moderate accord-
ing to previously described criteria20) and two seroneg-
ative age-matched controls were provided by the Na-
tional NeuroAIDS Consortium (Washington, DC) (Table 1).
Approval was obtained from the University of Nebraska
Medical Center institutional review board for these stud-
ies. Serial frozen sections (5 m thick) were cut and
double immunostained (indirect immunofluorescence) for
total OCC/HAM56 and CLD5/HAM56 or phospho-OCC
(at S507 and T382) and phospho-CLD5 (at T207) as
described.20
Assessment of Immunostaining
Semiquantitative assessment of immunostaining for
OCC, CLD5, phospho-OCC (at S507 and T382), and
phospho-CLD5 (at T207) was performed using five sec-
tions per brain, and three to seven brains per group.
Figure 2. Kinetics of substrate phosphorylation by GST-RhoK. Dose response curves of OCC-CT (A), CLD5-CT (B), and MLC (C). Km and Vmax values were
presented as mol/L and nmol/minute/mg, respectively, from the complied data of three independent experiments.
Figure 3. Time course of substrate phosphorylation by GST-RhoK. A and C:
OCC-CT (5 mol/L) or MLC (9 mol/L, C) was incubated with 200 mol/L
[-32P] ATP (10 Ci) and purified 1-g GST-RhoK in 100-l volume for 0 to
240 minutes, and a 10-l aliquot was mixed with Laemmli sampling buffer
and boiled for 5 minutes at each time point. The samples were subjected to
SDS-PAGE for CBB staining (top) and autoradiogram (bottom). B: The same
condition was applied to CLD5-CT peptide (800 mol/L, B), and 10-l
aliquots were spotted onto phosphocellulose membrane for each time point.
After extensive washing, the membrane was subjected to autoradiogram. D:
The time course of substrate phosphorylation by quantification of autoradio-
gram compiled from three independent experiments. y axis represents the
number of phosphates transferred to each substrate (mol/mol).
Figure 4. Phosphopeptide mapping of OCC-CT. A: Amino acid sequence of
purified OCC-CT. The underlined portions were determined by LC/MS/MS.
No significant phosphorylation sites were detected. B: Phosphorylation of
synthetic peptides corresponding to mouse OCC 378-387 with T382 (peptide
1), 500-510 with S507A mutation (peptide 2), and 500-510 with S504A mu-
tation (peptide 3) by purified GST-RhoK. The autoradiogram shows phos-
phorylation of peptides 1 and 3.
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Staining results were blindly quantified by the following
scoring system: 0 no positive staining in five20 fields
(1.0 mm2 each); 1  weak staining in less than 25% of
microvessels; 2  strong staining in 30 to 60% of mi-
crovessels; and 3  strong staining in more than 70% of
microvessels.
Results
We examined the phosphorylation of the cytoplasmic
C-terminal domains of mouse OCC and CLD5 using re-
combinant OCC 378-521 protein (OCC-CT) and synthetic
peptide corresponding to CLD5 199-218 (CLD5-CT) by
catalytic domain of RhoK 6-553 (GST-RhoK) in vitro (Fig-
ure 1, A and B). Dose-dependent increase of substrate
phosphorylation was observed in both OCC-CT (0 to 5
mol/L, Figure 1A) and CLD5-CT (0 to 1200 mol/L,
Figure 1B). MLC (0 to 12 mol/L, Figure 1C) was used as
a control substrate of GST-RhoK.21,31 GST-RhoK phos-
phorylated OCC-CT, CLD5-CT, and MLC with Km of 0.33,
34.6, and 1.47 mol/L and Vmax of 7.93, 15.1, and 55.3
nmol/minute/mg, respectively (Figure 2, A–C). The time
course of phosphorylation was also tested for the incu-
bation of 0 to 240 minutes (Figure 3, A–D). The MLC
phosphorylation reached plateau at 60 minutes (Figure 3,
C and D), whereas the phosphorylation of OCC-CT (Fig-
ure 3, A and D) and CLD5-CT (Figure 3, B and D) was
unsaturated up to 240 minutes. These data suggested
that RhoK could directly phosphorylate CLD5-CT and
OCC-CT; however, their phosphorylation kinetics were
not as efficient as MLC.
Our previous work using human brain tissues with
HIVE and in vitro BBBmodels (human BMVECs) indicated
that interactions between HIV-1-infected or uninfected
monocytes during their migration across the barrier 1)
decrease its integrity, 2) lead to phosphorylation of TJ
proteins via activation of RhoA and RhoK,20 and 3) inhi-
bition of RhoA/RhoK prevents monocyte migration, TJ
phosphorylation, and barrier impairment. The results pre-
sented here suggest that persistent RhoK activation (as
seen during monocyte infiltration during HIVE20) is nec-
essary for OCC and CLD5 phosphorylation.
To determine the phosphorylation sites of OCC-CT by
GST-RhoK, the phosphorylated OCC-CT protein was
subjected to phosphopeptide mapping using LC/MS/MS
with the system previously described.32 As shown in
Figure 4A, 107 amino acids of 148 residues (72%) were
covered by LC/MS/MS and no phosphorylation sites were
Figure 5. Phosphopeptide mapping of CLD5-CT peptide. A: Amino acid
sequence of CLD5-CT peptide. The underlined portion was determined by
LC/MS/MS. The phosphorylation site (T207) is in bold. MS/MS fragmentation
of trypsin-digested peptide fragment (mouse CLD5 205-218) detected T207
phosphorylation (Ions score, 47; expectation, 1.1e-0.05). B: Phosphorylation
of synthetic peptides corresponding to mouse clauding-5 199-208 (peptide
4), and 199-218 (peptide 5) by purified GST-RhoK. The autoradiogram shows
phosphorylation of peptide 5.
Figure 6. Detection of CLD5 and OCC phosphorylation by specific anti-
phosphopeptide antibodies. A–C: Top: CLD5 cytoplasmic sequence peptide
(A, 500 ng per spot) or OCC cytoplasmic protein fragment (B and C, 2 g per
spot) were incubated with GST-RhoK (200 ng/l) overnight at 30°C, and
spotted onto polyvinylidene difluoride membrane for dot-blotting using
anti-CLD5 pT207 (A), anti-OCC pT382 (B), or anti-OCC pS507 antibody (C).
Each antibody was preincubated with 10 g/ml of corresponding antigen
phosphopeptide before the immunoblotting for antigen absorption (bottom,
A–C). Lane 1, Two hundred ng of RhoK without ATP; lane 2, 200 ng of
RhoK with 1 mmol/L ATP; lane 3, 500 ng of CLD5 peptide with 200 ng of
RhoK without ATP; lane 4, 500 ng of CLD5 peptide with 200 ng of RhoK and
1 mmol/L ATP; lane 5, 500 ng of CLD5 pT207 phosphopeptide; lane 6, 2 g
of OCC-CT with 200 ng of RhoK without ATP; lane 7, 2 g of OCC-CT with
200 ng of RhoK and 1 mmol/L ATP; lane 8, 500 ng of OCC pT382 phos-
phopeptide; lane 9, 500 ng of OCC pS507 phosphopeptide.
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detected. To examine the uncovered sequences, we syn-
thesized corresponding peptides (peptide 1, 378-387;
peptide 2/3, 500-510), which contained one potential
phosphorylation site per peptide sequence (Figure 2B).
To distinguish the phosphorylation of S504 and S507,
either site was mutated to alanine (A) in peptides 2 and 3.
GST-RhoK phosphorylated peptides 1 and 3 (Figure 4B).
These data suggested that RhoK phosphorylated OCC at
T382 and S507.
To determine the phosphorylation of CLD5-CT, the
phosphorylated peptide was also analyzed by LC/MS/
MS, which detected phosphorylation of T207 (Figure 5A).
Because LC/MS/MS could not cover amino acids 199 to
204, the phosphorylation of S201 was determined by
generating synthetic peptides (peptide 4, 199 to 208; and
peptide 5,199 to 218). In peptide 4, T207 was mutated to
alanine (A) to distinguish phosphorylation of S201 and
T207 (Figure 5B). GST-RhoK phosphorylated peptide 5
but not 4 (Figure 5B). Our results indicated that RhoK
phosphorylated CLD5 at T207.
To further characterize TJ phosphorylation, we generated
and affinity-purified anti-phospho-OCC and phospho-
CLD5 antibodies using three synthetic phosphopeptides
against the determined sequences. These affinity-puri-
fied antibodies showed specificity to the target phospho-
residues without cross reactivity to nonphosphorylated
peptides of the same sequence or other phosphopep-
tides of different sequences (data not shown). Using
these antibodies, we examined if the cytoplasmic region
of OCC and CLD5 were phosphorylated by GST-RhoK at
the specific phosphorylation sites. The phosphorylation
Figure 7. Detection of OCC and CLD5 phosphorylation in COS-7 cells.
COS-7 cells were transfected with full-length wild-type mouse OCC or CLD5
mammalian expression vector, and treated or untreated with RhoK inhibitor
Y27632 (7.5 or 15 mol/L) for 16 hours. The plasma membrane samples were
lysed in 1% Trion X-100 and subjected to immunoprecipitation using 20 g
of anti-OCC (A), or CLD5 mouse monoclonal antibodies (B) plus protein A/G
Plus-Sepharose. Immunoblotting for OCC and p-OCC (pT382, A) or CLD5
and p-CLD5 (pT207, B) was performed on immunoprecipitated samples
using specific rabbit polyclonal antibodies. IP and blot (A and B) indicate
specific molecules for immunoprecipitation and immunoblotting, respec-
tively. A and B: NT; no transfection; OCC, transfected recombinant mouse
OCC; Cld-5, recombinant mouse CLD5. The number at the bottom indicates
changes in arbitrary unit of the immunoreactive band intensity of p-OCC
(pT382, A) or p-CLD5 (pT207, B) after Y27632 treatment.
Figure 8. Detection of LPA-induced OCC and CLD5 phosphorylation and
TEER reduction in mouse BMVECs. Western blots were performed using
novel phosphospecific antibodies, OCC pT382, OCC pS507, and CLD5 pT207
in mouse brain endothelial cells; nonphoshospecific antibodies recognizing
total OCC and total claudin5 are also indicated. A and C: Cells were cultured
under reduced serum conditions (1% FBS) for 24 hours and then stimulated
with 10 mol/L LPA for the indicated time points; or B and D: pretreated with
2 mol/L Y27632 for 1 hour followed by stimulation with 10 mol/L LPA for
30 minutes. Corresponding densitometry analysis of the Western blots is
shown below (C, D), the densitometry values represent the ratio of phos-
phorylated to unphosphorylated as compared with the nontreated (NT)
condition. E: Endothelial cell monolayers were formed on ECIS electrode
culture slides (described in Materials and Methods) and real time measure-
ments of TEER were acquired. The measurements shown represent record-
ings acquired at 3-minute intervals at the parameters described in the Mate-
rials and Methods. The single arrow designates the pretreatment (1 hour)
with 2 mol/L of Y27632 with or without co-incubation of 10 mol/L LPA as
shown by the double arrow. The data are presented as normalized resis-
tance for each condition, which is the resistance measured after treatment
over the resistance acquired before treatment introduction (typically 2600
/cm2). Representative data of three independent experiments are shown.
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of T207 of CLD5-CT and T382 of OCC-CT was detected
by respective specific antibody (Figure 6, A and B; lane
4). Phosphorylation of S507 of OCC-CT was undetect-
able, whereas positive control (phosphopeptide for
pS507; Figure 6C, lane 9) was identified by the specific
antibody. These data suggested that RhoK phosphory-
lated CLD5-CT at T207 and OCC-CT at T382, whereas
S507 of OCC-CT was minimally phosphorylated by RhoK.
Using these antibodies, we tested whether specific
residues were phosphorylated in cultured cells. Full-
Figure 9. Neuropathological features of HIVE in hu-PBL-NOD/SCID HIVE mice. Mice were reconstituted with human PBL and sacrificed 2 weeks after injection
of HIV-1-infected MDM in brains. Serial mouse brain sections stained with antibodies to human CD68 (A), HIV-p24 (B), human CD8 (C), Iba1 (D), or NF (E, F).
Primary Abs were detected by Vectastain Elite kit with DAB as a substrate. A and B: CD68 human MDM (arrow, A) in the basal ganglia were HIV-1 p24 (arrow,
B). C: CD8 lymphocyte infiltrated in the areas containing virus-infected macrophages (arrow). D: These areas featured prominent microglial reaction (Iba1,
arrow indicates location of MDM). E and F: Decreased staining for neuronal marker (NF) was found in injected hemisphere (arrow indicates area of injection,
E) as compared to contralateral (noninjected, F). Original magnifications: 200 (A–D); 40 (E, F).
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length wild-type OCC and CLD5 were transiently ex-
pressed in COS-7 cells, and replicate cells were treated
with RhoK inhibitor (Y27632). Cells were lysed, and the
plasma membrane fraction was collected followed by
immunoprecipitation and immunoblotting. We detected
endogenous phosphorylated OCC (p-OCC) in COS-7
(Figure 7A, lane 1). Overexpression of recombinant OCC
increased both total and phosphorylated p-OCC (Figure
7A, lane 2), and phosphorylation was reduced by RhoK
inhibitor (Figure 7A, lanes 3 and 4). COS-7 cells had no
endogenous CLD5 (Figure 7B, lane 1). Overexpression of
recombinant CLD5 showed phosphorylation at T207 (p-
CLD5; Figure 7B, lane 2), which was diminished by
Y27632 treatment (Figure 7B, lanes 3 and 4). Thus, both
OCC and CLD5 were phosphorylated at the specific
residues. Whereas OCC phosphorylation is partly depen-
dent on RhoK, CLD5 phosphorylation appears to be very
specific for RhoK.
We have also examined whether OCC and CLD5 phos-
phorylation is associated with functionally impaired TJs.
Confluent monolayers of mouse BMVECs (bEnd3 cell
line, known to express TJ molecules, such as OCC and
claudin-5, and widely used for BBB studies in
vitro24,25,33,34) with established TJs were treated with ly-
sophosphatidic acid (LPA), a known activator of RhoA35
and inducer of BBB impairment. LPA-induced RhoA ac-
tivation resulted in phosphorylation of OCC (at both S507
and T382) and CLD5 (at T207) (Figure 8, A and C). RhoA
activation also led to reduced barrier tightness, as indi-
cated by diminished TEER (Figure 8E). LPA-induced
phosphorylation of OCC and CLD5 and reduction in
TEER were prevented by RhoK inhibitor, Y27632 (Figure
8, B, D, and E), demonstrating RhoK-dependent signal-
ing in brain endothelial cells. These data demonstrate
direct association between OCC and CLD5 phosphory-
lation and functionally impaired TJs.
Finally, we examined the phosphorylation status of the
TJ proteins in the well established animal model of HIVE
(hu-PBL NOD/SCID HIVE mice) that reproduces a num-
ber of key features of human HIV-1 central nervous sys-
tem infection.36 Neuroinflammatory responses, neuronal
dysfunction, mononuclear cell infiltration across the BBB,
and BBB injury were reproduced in these animals.28 The
immune system of NOD/SCID mice was repopulated with
human PBL, and 1 week after PBL reconstitution, HIVE
was induced by stereotactic inoculation of autologous
HIV-infected MDM into the basal ganglia (generating hu-
PBL-NOD/SCID HIVE mice) (Figure 9, A and B). We
previously demonstrated specific antiviral cellular re-
sponses in this model and presence of CD8 T lympho-
cytes in areas containing MDM in the brain.28,29,36 The
presence of virus-specific cytotoxic T lymphocytes (CTL)
(Figure 9C) resulted in significant elimination of HIV-1
MDM as compared to control animals (injected with MDM
intracerebrally without prior PBL transfer).28,36,37 Astro-
gliosis and microglial reaction (Figure 9D) were evident in
these animals, being proportional to the level of mononu-
clear cell infiltration. Brain tissue of hu-PBL-NOD/SCID
HIVE mice showed neuronal injury (documented by de-
creased staining for NF; Figure 9, E and F) consistently
seen in the areas of neuroinflammation, which paralleled
neuronal and cognitive impairment as tested by hip-
pocampal electrophysiology and water maze tests.30 In
addition, mice developed viremia because of infection of
circulating CD4 lymphocytes.
TJ proteins of BMVECs were immunohistochemically
evaluated in animals intracerebrally injected with HIV-1-
infected MDM (HIVE mice) and sham-treated mice (5 l
of media without MDM). We examined seven brains of
mice with HIVE and three controls using antibodies to TJ
proteins and p-OCC and p-CLD5. As shown in Figure 10,
antibodies against total CLD5 and OCC stained brain
endothelial cells in sham and HIVE mouse brains (Figure
10, A, C, E, and G). In contrast, assessment of TJs by
phosphospecific CLD5 and OCC antibodies showed sig-
nificant increase in staining of HIVE mice (Figure 10, D
and H) as compared with sham-inoculated controls (Fig-
ure 10, E and F). Diminished staining of total OCC and
CLD5 (Figure 11, A–D) and increased expression of
phosphorylated TJ proteins (Figure 11, E–H) were found
in areas of mononuclear cell infiltration as well as on
some vessels without infiltration. These findings suggest
that other factors (such as proinflammatory molecules
Figure 10. Detection of OCC and CLD5 phosphorylation in brain tissues of
hu-PBL-NOD/SCID HIVE mice. A–H: Ten-m-thick frozen sections of mouse
brains were prepared at 14 days after sham injection (A, B, E, F) or intrace-
rebral injection of HIV-1-infected MDM (C, D, G, H). The sections were
stained with anti-CLD5 (A, C), anti-CLD5 pT207 (B, D), anti-OCC (E, G), or
anti-OCC pT382 antibodies (F, H) and fluorescence-conjugated secondary
antibodies. A–H: Oil immersion. Original magnifications, 1000.
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and viral proteins) could lead to BBB impairment. Al-
though contiguous OCC and CLD5 were easily detected
in control mice (Figure 11, I and J), antibodies to p-OCC
or p-CLD5 produced no staining (Figure 11, K and L).
Semiquantitative assessment of immunostaining with
phosphospecific antibodies indicated low score in con-
trol as compared to HIVE mice (Table 1).
We also tested antibodies to phosphorylated TJ pro-
teins in human brain tissues (four HIVE and two seroneg-
ative controls). As expected, CLD5 and OCC (Figure 12,
A and D) showed fragmented staining in areas containing
monocyte/macrophage infiltrate. Antibodies to p-CLD5
and p-OCC highlighted microvessels in brain tissues af-
fected by HIVE (Figure 12, B, C, E, and F). Control brains
demonstrated contiguous CLD5 immunostaining and few
perivascular macrophages (Figure 12G), whereas phos-
phospecific antibodies to TJ proteins produced no stain-
ing (Figure 12, H and I). Blind semiquantitative evaluation
of immunostaining with phosphospecific antibodies dem-
onstrated lower scores in controls as compared to HIVE
cases (Table 1). These data suggest that TJ phosphory-
lation was enhanced in HIVE paralleling BBB injury and
mononuclear cell infiltration. Thus, these antibodies could
be used as markers of BBB instability and RhoK-medi-
ated phosphorylation.
Discussion
Accumulating evidence suggests the role of RhoK in the
regulation of BBB integrity via modification of TJ proteins
ensuring barrier tightness.38 Our previous results pointed to
RhoK as a potential kinase of TJ proteins, activation of
which might be the molecular mechanism mediating BBB
dysfunction in neuroinflammation.20 This study demon-
strated that RhoK indeed phosphorylated cytoplasmic do-
mains in CLD5 and OCC at specific sites. Using mouse
BMVECs we demonstrated OCC and CLD5 phosphoryla-
tion at all three specific sites after RhoA/RhoK activation,
and these changes were accompanied by functional im-
pairment of the barrier and were prevented by specific
RhoK inhibitor. Furthermore, we detected phosphorylation
of TJ proteins by RhoK at the same sites using an in vitro
cellular system and HIVE model in vivo. Although OCC
phosphorylation was shown to be associatedwith loosening
of BBB in functional assays,39 its phosphorylation sites were
not thoroughly investigated. Andreeva and colleagues40
demonstrated that protein kinase C (PKC) could phosphor-
ylate OCC at S338 leading to its translocation to the cell-cell
contacts. Casein kinase 2 (CK2) phosphorylated OCC at
T375 and S379,41 and in vitro studies pointed to CK2 as
OCC kinase.42 However, the paucity of the phosphorylation
Figure 11. Expression of phosphorylated TJ proteins correlated with mononuclear cell infiltration in hu-PBL-NOD/SCID HIVE mice. Ten-m-thick frozen sections
of mouse brains were prepared at 14 days after intracerebral injection of HIV-1-infected MDM (A–H) or control mice (I–L). The sections were double
immunostained with anti-vimentin and anti-OCC (A, C, D, I), CLD5 (B, J), anti-CLD5 pT207 (E, F, K), or anti-OCC pS507 antibodies (G, H, L) and
fluorescence-conjugated secondary antibodies. Whereas TJs were well preserved in areas without mononuclear cell infiltrate (A), both CLD5 (B) and OCC (C, D)
showed fragmented staining in areas containing inflammatory cells (red, vimentin). Antibodies to p-CLD5 (pT207, E and F) and p-OCC (pS507, G and H)
highlighted microvessels featuring migration or perivascular accumulation of mononuclear cells (red). Brain endothelium outside of areas featuring inflammatory
infiltrate also featured positive staining with p-OCC or p-CLD5 (arrow), albeit less intensive (E and G) in HIVE mice. Control animals demonstrated contiguous
TJ immunostaining (OCC, I; and CLD5; J), whereas phosphospecific antibodies to TJ proteins produced no staining (K, L). Fluorescence-conjugated. Original
magnifications: 200 (A–C, E, G, I–L); 400 (D, F, H).
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sites by PKC contrasted with the multiple phosphorylation
residues found in previous reports8 suggesting the involve-
ment of other kinases in this process. In addition, OCC
could be phosphorylated on tyrosine residues by src-like
tyrosine kinase, c-Yes.43 This phosphorylation site at the C
terminus appeared to be critically important for its interac-
tion with ZO-1, -2, and -3 molecules.44
Little information is available regarding the direct phos-
phorylation of CLD5 by known protein kinases. Endothelial
cells exposed to cAMP demonstrated CLD5 phosphory-
lation at T207, in both protein kinase A (PKA)-dependent
and -independent manners in porcine brain endothelial
cells.45,46 Soma and colleagues45 admitted that its phys-
iological significance in the endothelial cell TJ remained
unclear. T207 is exactly the same site we found to be
phosphorylated by RhoK in the present study. Overex-
pression of the T207A mutant but not wild-type CLD5
restored the barrier tightness and decreased permeabil-
ity for mannitol (182 Da) in leaky lung endothelial cells.45
Thus, CLD5 T207 phosphorylation could be critical for the
BBB permeability for small molecules. We demonstrated
before that migration of HIV-1-infected or uninfected
monocytes caused diminished BBB integrity and phos-
phorylation of TJ proteins via activation of RhoA and
RhoK, and inhibition of RhoA/RhoK in endothelial cells
hampered monocyte migration, TJ phosphorylation, and
barrier impairment during their migration across the
monocyte barrier.20 Our results suggest that RhoK can
mediate PKA-independent phosphorylation of CLD5 at
T207 during interactions with monocytes.
The OCC phosphorylation by RhoK was less efficient as
compared to CLD5 and MLC. Although we observed endo-
genously phosphorylated OCC at T382 in COS-7 cells, the
phosphorylation of recombinant OCC was only partially in-
hibited by the RhoK-specific inhibitor Y27632. These data
suggest that although OCC is phosphorylated at T382, it is
only partially regulated by RhoK, and other kinases mediate
the phosphorylation. Thus, it will be of interest to character-
ize the OCC kinase that phosphorylates T382 using our
specific anti-phospho T382 antibody.
The CLD5 phosphorylation by RhoK at T207 was cor-
roborated by phosphopeptide mapping, radiolabeling,
Figure 12. Expression of phosphorylated TJ proteins in human brain tissues with HIVE. Ten-m-thick frozen sections of human brains with HIVE (A–F) or
controls (G–I) were cut. The sections were double immunostained with Ham56 (macrophage marker) and anti-CLD5 (A, G) or OCC (D), anti-CLD5 pT207 (B, C,
H), or anti-OCC pS507 antibodies (E, F, I) and fluorescence-conjugated secondary antibodies. CLD5 (green, A) and OCC (green, D) showed fragmented staining
in areas containing inflammatory cells (red, Ham56 monocyte/macrophage marker). Antibodies to p-CLD5 (pT207, B and C) and p-OCC (pS507, E and F)
highlighted microvessels (arrows). Control brains demonstrated contiguous CLD5 immunostaining (green) and few perivascular monocytes/macrophages (red)
(CLD5, G), whereas phosphospecific antibodies to TJ proteins produced no staining (OCC pS507, H; CLD5 pT207, I). Original magnifications: 200 (A, B, D, E,
G, H, I); 400 (C, F).
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and dot blot using anti-T207 antibody. T207 phosphory-
lation of full-length CLD5 was totally inhibited by Y27632
in COS-7 cells. These data strongly suggest that RhoK is
one of CLD5 kinases. Thus, RhoK appears to be involved
in BBB dysfunction through modification of TJs, because
CLD5 is abundantly expressed in brain microvasculature,
and its disruption by gene targeting results in BBB leak-
age.13,47 The phosphorylation of T207 may interfere with
its association with TJ anchoring molecules (such as
ZOs) leading to CLD5 destabilization at plasma mem-
brane. Further studies are necessary to characterize the
altered CLD5 interactions with other TJ molecules on its
phosphorylation. Importantly, phosphospecific antibod-
ies detected phosphorylation of CLD5 and OCC in mouse
endothelial cells because of RhoA/RhoK activation, and
TJ phosphorylation paralleled decreased barrier tight-
ness. Suppression of RhoK activity prevented these
changes, suggesting that RhoK inhibitors could protect
BBB. Tightness of the endothelial barrier as indicated by
TEER readings (typically 2600 /cm2) was higher than
the reported TEER of human BMECs (1500  1800 ).48
This may be attributable to the differences in experimen-
tal design (400 Hz reading instead of 4000 Hz) and
readout of parameters (resistance instead of imped-
ance). Indeed, Hartmann and colleagues49 reported
much higher TEER reading (15,000 ) from porcine
BMECs using the same instrument (ECIS model 1600R)
and readings (400 Hz) as ours.
Detection of phosphorylated CLD5 and OCC at cell
borders of BMVECs in HIVE mouse brains provides direct
evidence that chronic activation of RhoK phosphorylates
TJ proteins paralleling BBB dysfunction. Detection of
phosphorylated TJ proteins outside of mononuclear cell
infiltration suggests that other factors (such as proinflam-
matory cytokines, chemokines, or viral proteins) present
in the blood of HIVE animals could chronically disrupt
BBB as indicated by in vitro results.50 There is also spatial
and temporal delay in OCC and CLD5 phosphorylation
events and ligand stimulation or cell contact in vivo. Our
current in vitro work further addresses the molecular
mechanism of protein phosphorylation and barrier dys-
function under these conditions. Phosphospecific anti-
bodies generated by us can be used for monitoring the
chronic activation of TJ kinases, including RhoK, and the
extent of BBB leakage in vivo. Suppression of RhoK via
specific inhibitors or upstream Rho GTPases might be a
potential treatment approach for BBB injury associated
with neuroinflammation.
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